Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 486.5 INR 1.75% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

Cipla Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipla Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Cipla Ltd
NSE:CIPLA
Net Income (Common)
â‚ą44.8B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Income (Common)
â‚ą55.7B
CAGR 3-Years
47%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Income (Common)
â‚ą110.5B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
6%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Net Income (Common)
â‚ą41.9B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
17%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Net Income (Common)
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Net Income (Common)
â‚ą19.1B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipla Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals

Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global markets and local needs has positioned Cipla not only as a trusted brand in India but also as a key player in over 80 countries worldwide. For investors, Cipla represents a compelling opportunity due to its strategic initiatives aimed at sustaining growth amidst challenging market dynamics. The company's impressive financial performance, characterized by steady revenue growth and healthy margins, underscores its operational efficiency and market-leading position. Cipla’s proactive approach to collaborations, licensing agreements, and technological advancements indicates a future that embraces pharmaceutical innovations while maintaining cost-effective solutions. Furthermore, its commitment to sustainability and ethical practices resonates well in today's socially conscious investing landscape. As healthcare demands continue to rise globally, Cipla's mission to enhance access to vital medications stands to benefit both patients and shareholders alike.

CIPLA Intrinsic Value
1 173.46 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Cipla Ltd's Net Income (Common)?
Net Income (Common)
44.8B INR

Based on the financial report for Sep 30, 2024, Cipla Ltd's Net Income (Common) amounts to 44.8B INR.

What is Cipla Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
15%

Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Cipla Ltd have been 20% over the past three years , 22% over the past five years , and 15% over the past ten years .

Back to Top